BRPI0413876A - tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos - Google Patents

tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos

Info

Publication number
BRPI0413876A
BRPI0413876A BRPI0413876-7A BRPI0413876A BRPI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A
Authority
BR
Brazil
Prior art keywords
sup
thienopyridin
phenylacetamides
derivatives useful
antiangiogenic agents
Prior art date
Application number
BRPI0413876-7A
Other languages
English (en)
Inventor
Mingying He
Robert Steven Kania
Jihong Lou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0413876A publication Critical patent/BRPI0413876A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

"TIENOPIRIDIN-FENILACETAMIDAS E SEUS DERIVADOS úTEIS COMO AGENTES ANTIANGIOGêNICOS". A invenção está relacionada a compostos representados pela Fórmula (I): e com suas prodrogas, sais ou solvatos farmaceuticamente aceitáveis dos referidos compostos ou das referidas prodrogas, em que cada um de X¬ 1¬-X¬ 5¬ e R¬ 1¬-R¬ 5¬ são aqui definidos. A invenção está também relacionada com formulações farmacêuticas que contêm os compostos de Fórmula (I) e aos métodos de tratamento de distúrbios hiperproliferativos em mamífero mediante a administração de compostos de Fórmula (I).
BRPI0413876-7A 2003-08-29 2004-08-16 tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos BRPI0413876A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49907703P 2003-08-29 2003-08-29
PCT/IB2004/002688 WO2005021554A1 (en) 2003-08-29 2004-08-16 Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents

Publications (1)

Publication Number Publication Date
BRPI0413876A true BRPI0413876A (pt) 2006-10-24

Family

ID=34272772

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413876-7A BRPI0413876A (pt) 2003-08-29 2004-08-16 tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos

Country Status (10)

Country Link
US (1) US7208500B2 (pt)
EP (1) EP1660504B1 (pt)
JP (1) JP2007504122A (pt)
AT (1) ATE412655T1 (pt)
BR (1) BRPI0413876A (pt)
CA (1) CA2536321A1 (pt)
DE (1) DE602004017479D1 (pt)
ES (1) ES2314444T3 (pt)
MX (1) MXPA06002296A (pt)
WO (1) WO2005021554A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007107167A (ru) 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
KR20070084172A (ko) 2004-10-12 2007-08-24 아스트라제네카 아베 퀴나졸린 유도체
DK1904504T3 (da) 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
US8093264B2 (en) 2005-05-20 2012-01-10 Methylgene Inc. Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
US20090170131A1 (en) * 2006-05-09 2009-07-02 Juri Gelovani Agents for Imaging Apoptosis
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
EP2332536A1 (en) 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
GB0901834D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
GB0901835D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MX2012002596A (es) * 2009-09-03 2012-07-03 Allergan Inc Compuestos como moduladores de tirosina cinasas.
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP3293177A4 (en) * 2015-04-07 2018-12-12 Guangdong Zhongsheng Pharmaceutical Co., Ltd Tyrosine kinase inhibitor and pharmaceutical composition comprising same
WO2018156946A1 (en) 2017-02-24 2018-08-30 Humanetics Corporation Protecting tissue and mitigating injury from radiation-induced ionizing events
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
CN111825605B (zh) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 芳基酮酰胺类化合物及其制备方法和用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1514934B1 (en) * 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
BR9506936A (pt) 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
DE69519751T2 (de) * 1995-04-20 2001-04-19 Pfizer Inc., New York Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
WO1997049700A1 (en) * 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
DK0923585T3 (da) 1996-07-18 2002-07-01 Pfizer Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0946554A1 (en) 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
EA002594B1 (ru) 1997-02-03 2002-06-27 Пфайзер Продактс Инк. Производные арилсульфониламиногидроксамовой кислоты
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
JP2001525816A (ja) 1997-05-12 2001-12-11 ザ ケネディー インスティチュート オブ リューマトロジー 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
EP1062218A1 (en) * 1998-03-12 2000-12-27 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
AR018408A1 (es) 1998-05-29 2001-11-14 Sugen Inc Compuesto pirrol sustituido 2-indolinona, composicion farmaceutica que lo comprende, uso de dicho compuesto en un metodo ''in vivo'' y su uso para lapreparacion de dicha composicion
CA2331399A1 (en) * 1998-06-26 2000-01-06 Shuichi Furuya Thienopyridine compounds, their production and use
US6383744B1 (en) * 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
WO2000016781A1 (en) 1998-09-18 2000-03-30 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
BR9916518A (pt) 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU7070800A (en) 1999-08-27 2001-03-26 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
US6211164B1 (en) * 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
JP2003527441A (ja) 2000-03-22 2003-09-16 グラクソ グループ リミテッド 細胞周期を阻止する薬剤及び抗体を含む医薬
RU2002129574A (ru) 2000-03-31 2004-04-20 Имклон Системс Инкорпорейтед (Us) Лечение неплотных опухолей молочной железы антагонистами рецепторов сосудистого эндотелиального фактора роста
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DK1297016T3 (da) 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
WO2002030453A1 (en) 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
ES2290199T3 (es) 2000-11-22 2008-02-16 Novartis Ag Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce.
WO2002064170A1 (en) 2001-02-09 2002-08-22 Children's Medical Center Corporation A method for treating cancer and increasing hematocrit levels
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003000194A2 (en) * 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
JP2005515967A (ja) 2001-07-13 2005-06-02 イムクローン　システムズ　インコーポレイティド 乳癌を治療するためのｖｅｇｆｒ−１抗体
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
PT1441714E (pt) 2001-10-25 2008-03-10 Novartis Ag Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2

Also Published As

Publication number Publication date
US7208500B2 (en) 2007-04-24
JP2007504122A (ja) 2007-03-01
EP1660504A1 (en) 2006-05-31
EP1660504B1 (en) 2008-10-29
MXPA06002296A (es) 2006-05-22
US20050090509A1 (en) 2005-04-28
DE602004017479D1 (de) 2008-12-11
WO2005021554A1 (en) 2005-03-10
ATE412655T1 (de) 2008-11-15
ES2314444T3 (es) 2009-03-16
CA2536321A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
GT199900139A (es) Derivados de quinolin-2-ona ùtiles como agentes contra el càncer.
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
TR200102136T2 (tr) Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler.
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
EA200600892A1 (ru) Новые хинолиновые производные
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
BG105365A (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
RS20050469A (en) Pyrrolopyrimidine derivatives
SG159388A1 (en) Antibacterial agents
GEP20094736B (en) Prodrugs of piperazine and substituted piperidine antiviral agents
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
ATE330956T1 (de) Bizyklisch substituierte 4- aminopyridopyrimidinderivate
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos
DOP2003000595A (es) Indolil-urea derivado de tienopiridinas utiles como agentes antiangionicos,y procedimientos para su uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.